• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC TO-T/A filed by Calliditas Therapeutics AB

    9/18/24 9:02:28 AM ET
    $CALT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CALT alert in real time by email
    SC TO-T/A 1 sctot0924_asahikasei.htm FORM SC TO-T/A

      

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    ________________________

    SCHEDULE TO

    Tender Offer Statement under Section 14(d)(l) or 13(e)(l)
    of the Securities Exchange Act of 1934
    (Amendment No. 4)

    ________________________

    CALLIDITAS THERAPEUTICS AB
    (Name of Subject Company (Issuer))

    ________________________

    ASAHI KASEI CORPORATION
    (Offeror)

    ________________________

    Common Shares (“Shares”), quota value SEK 0.04 per Share

    American Depositary Shares (“ADSs”), each representing two Common Shares,
    quota value SEK 0.04 per Share
    (Title of Class of Securities)

    13124Q1061
    (CUSIP Number of Class of Securities)

    ________________________

    Shinichiro Haga
    Lead Executive Officer and Senior General Manager, Corporate Strategy
    1
    -1-2 Yurakucho, Chiyoda-ku, Tokyo, Japan 100-0006
    +81
    -3-6699-3000
    (Name, address and telephone number of person authorized to receive
    notices and communications on behalf of filing persons)

    ________________________

    Copies to:

    Benet J. O’Reilly, Esq.
    Adam J. Brenneman, Esq.
    Kimberly R. Spoerri, Esq.
    Cleary Gottlieb Steen & Hamilton LLP
    One Liberty Plaza
    New York, New York 10006
    (212) 225
    -2000

    ________________________

    ☐

     

    Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

    Check the appropriate boxes below to designate any transactions to which the statement relates:

       

    ☒      third-party tender offer subject to Rule l 4d-l.

       

    ☐      issuer tender offer subject to Rule l3e-4.

       

    ☐      going-private transaction subject to Rule 13e-3.

       

    ☐      amendment to Schedule l3D under Rule l3d-2.

    Check the following box if the filing is a final amendment reporting the results of the tender offer: ☒

    If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

       

    ☐      Rule l3e-4(i) (Cross-Border Issuer Tender Offer)

       

    ☒      Rule 14d-l(d) (Cross-Border Third-Party Tender Offer)

    ____________

    1        No CUSIP number exists for the underlying Common Shares, as the Common Shares are not traded in the United States. The CUSIP number 13124Q106 is only for the American Depositary Shares representing Common Shares.

      

     

    EXPLANATORY NOTE

    On September 16, 2014, Amendment No. 4 to the Schedule TO (defined below) was filed by Asahi Kasei Corporation, a Japanese corporation (the “Original Amendment No. 4”). The Original Amendment No. 4 was intended to be the final amendment of the Schedule TO. However, the box next to “Check the following box if the filing is a final amendment reporting the results of the tender offer” was inadvertently not checked in the Original Amendment No. 4. This Amendment No. 4 is intended to correct this error. This Amendment No. 4 replaces and supersedes the Original Amendment No. 4 in its entirety.

    * * *

    This Amendment No. 4 (this “Amendment”) amends and supplements the Schedule TO (as amended August 1, 2024, August 13, 2024, and September 3, 2024 and together with any subsequent amendments and supplements thereto, the “Schedule TO”) filed with the Securities and Exchange Commission (the “Commission”) on July 18, 2024, by Asahi Kasei Corporation, a Japanese corporation (“Buyer” or the “Offeror”), in relation to its tender offer to purchase all of the outstanding common shares, quota value SEK 0.04 per share, held by U.S. Persons (the “Shares”) and all of the outstanding American Depositary Shares, each representing two common shares, quota value SEK 0.04 per share, whether or not held by U.S. Persons (the “ADSs” and, together with the Shares, the “Offer Securities”) of Calliditas Therapeutics AB, a company incorporated under the laws of Sweden (“Calliditas” or the “Company”), upon the terms and subject to the conditions set forth in the Offer to Purchase, dated as of July 18, 2024 (the “Offer to Purchase”), a copy of which is attached to the Schedule TO as Exhibit (a)(1)(a), and in the related Letter of Transmittal for ADSs (the “ADS Letter of Transmittal”) and Acceptance Form for Shares (the “Acceptance Form for Shares”, which, together with the Offer to Purchase, the ADS Letter of Transmittal and other related materials, as each may be amended or supplemented from time to time, collectively constitute the “U.S. Offer”), copies of which are attached to the Schedule TO as Exhibit (a)(1)(B) and Exhibit (a)(1)(C), respectively. The U.S. Offer was made in conjunction with an offer by Buyer in Sweden directed to holders of Shares, but not holders of ADSs (the “Swedish Offer,” and together with the U.S. Offer, the “Offers”).

    This Amendment is being filed solely to amend and supplement items to the extent specifically provided herein. Except as otherwise set forth in this Amendment, the information set forth in the Schedule TO, including all exhibits thereto, remains unchanged and is incorporated herein by reference to the extent relevant to the items in this Amendment. This Amendment should be read together with the Schedule TO.

    Items 1 through 9 and Item 11.

    The Offer to Purchase and Items 1 through 9 and Item 11 of the Schedule TO, to the extent such Items incorporate by reference the information contained in the Offer to Purchase, are hereby amended and supplemented as follows:

    The following paragraphs are added thereto:

    “The Subsequent U.S. Offering Period expired as scheduled at 6:00 p.m., Eastern time, on September 13, 2024. The Share Tender Agent has advised Buyer that, as of 6:00 p.m., Eastern time, on September 13, 2024, 2,705,385 Shares have been validly tendered and not properly withdrawn during the Subsequent U.S. Offering Period and the subsequent offering period by Buyer in Sweden of the Swedish Offer. The ADS Tender Agent has advised Buyer that, as of 6:00 p.m., Eastern time, on September 13, 2024, 18,947 ADSs have been validly tendered and not properly withdrawn during the Subsequent U.S. Offering Period. These Shares and ADSs collectively represent approximately 5.08% of the outstanding Shares as of such time. As a result, Buyer will own 53,156,176 Shares, corresponding to a total of 98.38% of the outstanding Shares, upon settlement of the Subsequent U.S. Offering Period and the subsequent offering period by Buyer in Sweden of the Swedish Offer. On September 16, 2024, Buyer accepted for payment all Offer Securities that were validly tendered during the Subsequent U.S. Offering Period.

    On September 13, 2024, the Company filed a Form 25, Notification of Removal from Listing and/or Registration with the Commission. The Company has also applied for delisting of the Shares from Nasdaq Stockholm.

    1

    On September 16, 2024, Buyer issued a press release in Sweden announcing the expiration, results and consummation of the subsequent offering period by Buyer in Sweden of the Swedish Offer, which is directed to holders of Shares, but not holders of ADSs. The press release is attached as Exhibit (a)(5)(T) hereto and incorporated herein by reference.”

    Item 12.     Exhibits.

    Item 12 of the Schedule TO is hereby amended and supplemented by adding the following exhibits:

    Exhibit No.

     

    Description

    (a)(5)(T)

     

    English version of Swedish press release dated September 16, 2024.*

    ____________

    *        Filed herewith.

    2

    SIGNATURES

    After due inquiry and to the best of their knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: September 18, 2024

    Asahi Kasei Corporation

       

    By:

     

    /s/ Shinichiro Haga

       

    Name:

     

    Shinichiro Haga

       

    Title:

     

    Attorney-in-Fact pursuant to Power of Attorney attached to the Schedule TO

       

    3

    Get the next $CALT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CALT

    DatePrice TargetRatingAnalyst
    6/20/2023$60.00Buy
    H.C. Wainwright
    3/1/2023$18.00Neutral
    Guggenheim
    12/20/2021$52.00 → $62.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CALT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for TARPEYO issued to CALLIDITAS THERAPEUTICS AB

      Submission status for CALLIDITAS THERAPEUTICS AB's drug TARPEYO (ORIG-1) with active ingredient BUDESONIDE has changed to 'Approval' on 12/15/2021. Application Category: NDA, Application Number: 215935, Application Classification: Type 5 - New Formulation or New Manufacturer

      12/20/21 3:40:41 PM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Calliditas Therapeutics AB

      SC 13D/A - Calliditas Therapeutics AB (0001795579) (Subject)

      9/23/24 7:32:15 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Calliditas Therapeutics AB

      SC 13D/A - Calliditas Therapeutics AB (0001795579) (Subject)

      9/17/24 7:55:03 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Calliditas Therapeutics AB

      SC 13G/A - Calliditas Therapeutics AB (0001795579) (Subject)

      9/11/24 7:42:16 PM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALT
    Leadership Updates

    Live Leadership Updates

    See more
    • Calliditas Therapeutics appoints Maria Törnsén as President North America

      STOCKHOLM, Jan. 7, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ:CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that Maria Törnsén has been appointed to the position of President North America. Ms Törnsén will be responsible for all US based operations and will report to the CEO. Maria Törnsén has broad commercial leadership experience having spent more than 20 years in the biopharma industry in senior commercial roles. Most recently Ms Törnsén held the position of Chief Commercial Officer at Passage Bio, prior to which she was SVP General Manager US at Sarepta Therapeutics. Prior to joining Sarepta she serv

      1/7/24 11:19:00 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celularity Appoints Industry Leader Diane Parks to its Board of Directors

      FLORHAM PARK, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced the appointment of Diane Parks to its Board of Directors. Ms. Parks, an executive with deep experience in the commercialization of novel immuno-oncology therapies, has led the successful launch of numerous hematology and cancer therapies at large pharmaceutical and biotech companies, including Kite Pharma, Inc. (now part of Gilead Sciences, Inc.), Amgen Inc., and Genentech, Inc. (now part of Roche Holdings, Inc.). "It is with great pleasure we welcome Diane to the Cel

      6/3/22 8:00:00 AM ET
      $CALT
      $CELU
      $CTIC
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phathom Pharmaceuticals Announces Appointment of Molly Henderson as Chief Financial and Business Officer

      FLORHAM PARK, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Molly Henderson to the position of Chief Financial and Business Officer. Ms. Henderson will join the Company effective April 5, 2022.       Ms. Henderson most recently served as Chief Financial Officer of UroGen Pharma (NASDAQ:URGN), a commercial-stage biopharmaceutical company focused on building novel treatments for specialty cancers and urologic disease. She brings over two decades of global finance expertise and has

      3/22/22 8:02:00 AM ET
      $CALT
      $PHAT
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALT
    Financials

    Live finance-specific insights

    See more
    • Calliditas Interim Report January to June 2024

      STOCKHOLM, Aug. 13, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ:CALT) (STO: CALTX) : April to June 2024 (compared to April to June 2023) Net sales amounted to SEK 559.8 million, of which TARPEYO® net sales amounted to SEK 493.4 million, for the three months ended June 30, 2024. For the three months ended June 30, 2023, net sales amounted to SEK 269.4 million, of which TARPEYO net sales amounted to SEK 259.2 million.Operating loss amounted to SEK 31.5 million and SEK 75.2 million for the three months ended June 30, 2024, and 2023, respectively. However, expenses related to the Asahi Kasei offer and expenses related to provisions for social security contribution for incentive prog

      8/13/24 1:22:00 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Invitation to the presentation of Calliditas's interim report January - June 2024

      STOCKHOLM, Aug. 5, 2024 /PRNewswire/ -- Calliditas's interim report for the second quarter, April - June 2024 will be published in Swedish and English on Tuesday 13 August 2024 at 07.00 a.m. CET. A combined audio cast and telephone conference with the opportunity to ask questions will be held at 14.30 p.m. CET on the same day, with CEO Renée Aguiar-Lucander and CFO Fredrik Johansson, CMO Richard Philipson and President North America Maria Törnsén. The presentation will be given in English. Link to the webcast:  https://ir.financialhearings.com/calliditas-therapeutics-q2-report-2024 To participate via conference call please register via this link: https://conference.financialhearings.com/tel

      8/5/24 1:19:00 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)

      STOCKHOLM, June 17, 2024 /PRNewswire/ -- The following resolutions were passed at Calliditas Therapeutics AB (publ) ("Calliditas") annual general meeting held today, on 17 June 2024, in Stockholm. Adoption of income statement and balance sheet for the financial year 2023 and discharge from liability The annual general meeting resolved to adopt the income statement and the consolidated income statement for the financial year 2023 as well as the balance sheet and consolidated balance sheet as of 31 December 2023. The members of the Board of Directors and the CEO were discharged from liability for the financial year 2023. Allocation of profit or loss                                            

      6/17/24 12:01:00 PM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALT
    SEC Filings

    See more
    • SEC Form 15F-12B filed by Calliditas Therapeutics AB

      15F-12B - Calliditas Therapeutics AB (0001795579) (Filer)

      9/23/24 4:44:35 PM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by Calliditas Therapeutics AB

      25-NSE - Calliditas Therapeutics AB (0001795579) (Subject)

      9/20/24 4:45:11 PM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC TO-T/A filed by Calliditas Therapeutics AB

      SC TO-T/A - Calliditas Therapeutics AB (0001795579) (Subject)

      9/18/24 9:02:28 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALT
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $CALT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm

      STOCKHOLM, Sept. 16, 2024 /PRNewswire/ -- Nasdaq Stockholm has decided that Calliditas Therapeutics AB (publ) will be delisted from Nasdaq Stockholm. The last day of trading in the share will be on Thursday, October 10, 2024. For further information, please contact: Åsa Hillsten, Head of IR & Sustainability, Calliditas Tel.: +46 76 403 35 43, Email: [email protected] The information was sent for publication, through the agency of the contact person set out above, on September 16, 2024 at 15:30 CET. About Calliditas Calliditas Therapeutics is a biopharma company headquartered in Stockholm, Sweden, focused on identifying, developing, and commercializing novel treatments in orphan in

      9/16/24 9:46:00 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Notice of extraordinary meeting of Calliditas Therapeutics AB (publ)

      STOCKHOLM, Sept. 3, 2024 /PRNewswire/ -- The shareholders of Calliditas Therapeutics AB (publ) ("Calliditas Therapeutics"), Reg. No. 556659-9766, with registered office in Stockholm, are summoned to the extraordinary general meeting on Monday 30 September 2024 at 12:00 p.m. CEST at Advokatfirman Vinge's premises on Smålandsgatan 20, SE-111 46, Stockholm, Sweden. Registration starts at 11:30 a.m. CEST. Background Asahi Kasei Corporation ("Asahi Kasei"), which has announced that the public offer made regarding the company's shares has been accepted to such extent that Asahi Kasei becomes the owner of more than 90 per cent of the shares and votes in the company, has requested the board of dire

      9/3/24 7:13:00 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei

      STOCKHOLM, Sept. 3, 2024 /PRNewswire/ -- Following the announcement by Asahi Kasei Corporation ("Asahi Kasei") on September 2, 2024 that it controls more than 90 percent of the outstanding shares of Calliditas Therapeutics AB (NASDAQ:CALT) ("Calliditas" or the "Company"), and declared its offers to purchase all of the outstanding Common Shares and ADSs of Calliditas unconditional and intends to initiate compulsory redemption of the remaining shares of the Company, the Board of Directors of Calliditas has resolved, in accordance with a request from Asahi Kasei, to take certain corporate actions. Delisting of Common Shares and Delisting, Deregistration, and Termination of ADS Program In light

      9/3/24 6:31:00 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Calliditas Therapeutics AB with a new price target

      H.C. Wainwright initiated coverage of Calliditas Therapeutics AB with a rating of Buy and set a new price target of $60.00

      6/20/23 7:20:21 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Calliditas Therapeutics AB with a new price target

      Guggenheim initiated coverage of Calliditas Therapeutics AB with a rating of Neutral and set a new price target of $18.00

      3/1/23 6:14:34 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Calliditas Therapeutics with a new price target

      HC Wainwright & Co. reiterated coverage of Calliditas Therapeutics with a rating of Buy and set a new price target of $62.00 from $52.00 previously

      12/20/21 6:22:01 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care